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Abstract
Purpose: Lymphoproliferative neoplasms are the largest and most frequently diagnosed entities in the group of haema­
tological malignancies. The aim of the study was to assess whether apparent diffusion coefficient (ADC) measured on 
the first day of the second cycle of chemotherapy could be a predictor of prognosis and of the final treatment’s outcome.
Material and methods: The study included 27 patients with diagnosed Hodgkin’s and non­Hodgkin’s lymphoma, who 
had magnetic resonance (MR) performed with diffusion weighted imaging/apparent diffusion coefficient (DWI/ADC) 
before and on the first day of the second cycle of chemotherapy. Imaging was performed using a 1.5 T MR scanner. 
ADC was measured in lymphoma infiltration in the area of the lowest signal in the ADC map and the highest signal 
on b 800 images in post­treatment study. After that, the corresponding area was determined in a pre­treatment study 
and an ADC value was measured. 
Results: The difference between ADC values in pre­treatment (ADC = 720 mm2/s) and post­treatment (ADC = 1059 mm2/s) 
studies was statistically significant (p < 0.001). Cutoff values for estimating response to treatment were established at the 
level of ADC 1080 mm2/s, and ADC to muscle ratio at 0.82 in post­treatment study. Patients with ADC > 752 mm2/s 
before treatment manifested lower probability of progression than patients with ADC < 752 mm2/s. 
Conclusions: ADC measurement’s before treatment and on the first day of the second cycle of chemotherapy can be 
used as a prognostic marker in lymphoma therapy. ADC values lower than 1080 mm2/s and an increase of the ratio 
after the treatment can be considered as a marker of disease progression. 
Key words: lymphoma, Hodgkin’s lymphoma, magnetic resonance imaging, diffusion MRI. 
Correspondence address: 
Mateusz Patyk, Department of General and Paediatric Radiology, Wrocław Medical University, 68 M. Curie-Skłodowskiej St., 50-369 Wrocław, Poland, 
phone: +48 71 784 26 51, e-mail: mtpatyk@gmail.com
Authors’ contribution: 
A Study design ∙ B Data collection ∙ C Statistical analysis ∙ D Data interpretation ∙ E Manuscript preparation ∙ F Literature search ∙ G Funds collection
Introduction
Lymphoproliferative neoplasms are the largest and most 
frequently diagnosed entities in the group of haematolog­
ical malignancies [1] staging, and response assessment of 
patients with Hodgkin lymphoma (HL). Over the years 
an increasing trend of incidence rate of lymphomas has been 
noticed. Currently it amounts to approximately 20­22 new 
cases per 100,000 persons per year, according to various 
regi sters [2, 3].
Mateusz Patyk, Jacek Kwiatkowski, Aleksander Pawluś et al.  
e2 © Pol J Radiol 2018; 83: e210-e214
Introducing new diagnostic tools to everyday prac­
tice allows more precise evaluation of disease. One of the 
most important aspects is the evaluation of response to 
treatment. Accurate assessment of early response is crucial 
to the diagnosis of lymphoma. This allows patients to be 
distinguished within the high­risk groups and to modi­
fy ineffective treatment in the early stages. This is of ut­
most importance in the context of individualisation and 
optimisation of treatment, contributing to positive effects 
for both the patients and for the entire health care system 
(economic effect).
Positron emission tomography computed tomog­
raphy (PET/CT) scanning is currently considered to be 
the reference method for the assessment of response in 
the majority of lymphomas, especially in the evaluation 
of early response to treatment in HL [4]who underwent 
both [18F]­FDG­PET/CT and whole­body MRI (including 
T1­ and diffusion­weighted sequences). There are several 
studies describing the potential role of diffusion weight­
ed imaging (DWI) in the diagnosis and evaluation of re­
sponse to treatment of lymphomas [5] 31 females, medi­
an age – 42 years, range 15­86 years. DWI is a technique 
in which the image contrast reflects the in vivo changes 
in the motion of water molecules (Brownian motion) 
in tissues. A supplemental tool in DWI is the apparent 
diffusion coefficient (ADC) map, acquired by post­pro­
cessing of the obtained DWI images [6]. ADC allows for 
quantitative definition of diffusion parameters (in mm2/s) 
(Fig. 1). The applicability of DWI has been confirmed e.g. 
in the detection of ischaemic stroke or in the evaluation of 
breast or prostate gland abnormalities. Numerous recent 
studies associated with DWI have focused on utilisation of 
its tools to evaluate response to treatment in oncological 
patients. Haematological diseases seem to be a very per­
spective area for the DWI tools, e.g. due to high cellularity 
of lymphoma infiltration [7].
The purpose of this study was the assessment of the 
DWI/ADC imaging protocol in the evaluation of the ear­
ly response to treatment of Hodgkin’s and non­Hodgkin’s 
lymphomas. Additionally, we analysed whether the ADC 
measured on the first day of the second cycle of chemo­
therapy could be a predictor of prognosis and of the final 
outcome of the treatment.
Material and methods
The study included the final group of 27 patients with 
Hodgkin’s and non­Hodgkin’s lymphoma diagnosed 
(Table 1). They underwent MRI of the area in question be­
fore the treatment and on the first day of the second cycle 
of chemotherapy. All examinations were performed using 
a 1.5 T MR unit with a conventional phased array body 
coil. The DWI was performed using a standard protocol, 
namely the single­shot spin­echo­planar imaging (EPI) in 
the axial plane, with the following parameters: TR 5200­
6000 ms, TE – 72 ms, voxel size 2 × 2 × 5, Bw 1448 Hz/px, 
b values 50, 400, and 800, 30­45 slices, duration ~6 min.
ADC maps were calculated with a dedicated work­
station. ADC values were measured in lymphoma infil­
tration in the area of the lowest signal in the ADC map 
images in post­treatment study, paying particular attention 
to avoid areas that could affect the DWI signal, e.g. hae­
matomas. The corresponding area was determined in the 
pre­treatment study, and the pre­treatment ADC values 
were measured afterwards. Only oval­shaped ROIs were 
used to measure the ADC values, and the size thereof was 
adjusted to the size of the area with the lowest ADC signal. 
The ADC values were analysed as an independent value 
and as a ratio – dorsal muscles were used as the reference 
organs (Fig. 2). A Wilcoxon test was performed to verify 
the difference between the ADC values before and after 
the treatment. The ROC curve was used to determine the 
cut­off values, and the odds ratio was calculated.
Results
There was a statistically significant difference between 
the ADC values in the pre­treatment (ADC = 720 mm2/s) 
and post­treatment (ADC = 1059 mm2/s) studies (Fig. 3). 
The ADC value increased significantly in both groups 
(Table 2, Fig. 4). In the group of patients with diagnosed 
HL the ADC increased by 344 mm2/s on average, and by 
206 mm2/s in patients with non­Hodgkin’s lymphoma, 
respectively. The cut­off values used for estimation of 
the response to the treatment were established at the level 
Figure 1. MRI-DWI ADC map in a patient with non-Hodgkin’s lymphoma
Table 1. Patients’ characteristics (N = 27)
Factor
Sex, male/female (n) 22/5
Age, mean ± SD (years) 41.5 ± 15.6
Age, median (years) 41 
Hodgkin’s lymphoma (n) 8
Non-Hodgkin’s lymphoma (n) 19
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of ADC 1080 mm2/s, and the ADC to muscle ratio 0.82 
in the post­treatment study (Fig. 3). The patients with 
ADC > 752 mm2/s before treatment demonstrated low­
er probability of progression than the patients with ADC 
< 752 mm2/s (p = 0.046). Considering the changes be­
tween the studies, an increase of the ADC by 34.5% and 
an increase of the ratio of by 32.5% were determined as 
the cut­off values. The highest odd ratios were calculated 
proving that the pre­examination ADC or the ratio itself 
would serve best for an assessment of the low response 
risk. 
Discussion 
Advanced imaging techniques play an important role in 
the diagnosis, evaluation, and staging of lymphomas [1]
staging, and response assessment of patients with HL. De­
spite the fact that the sensitivity and specificity of PET/
CT with 18F­FDG depends on the histological lymphoma 
subtype, the Lugano classification of malignant lympho­
mas recommends the use of PET/CT with 18F­FDG as the 
reference imaging technique combined with bone mar­
row biopsy (BM) [1, 8] staging, and response assessment 
of patients with HL. There are several studies describing 
the role of whole­body MRI, with the DWI/ADC meas­
urement as a diagnostic tool in the evaluation of patients 
with lymphoma [9­12] metabolic tumor volume (MTV). 
The potential role of the measurements of DWI/ADC 
in patients with non­Hodgkin’s lymphoma was well de­
scribed in 2012 by Chen and Zhong. The authors reported 
that WB­DWI can be adopted to detect morphological 
changes of lesions, but moreover it provides important 
functional information about the growth and decline pro­
cess of tumour cells [13]. The effectiveness of PET­CT and 
MRI DWI/ADC in the initial stages of malignant lympho­
ma was analysed in another study. The authors compared 
these two methods in a pretherapeutic context and agree­
ment for Ann Arbor staging. They reported high repeat­
Figure 3. Comparison of the apparent diffusion coefficient (ADC) values 
before and after the treatment (Student’s t-test, independent samples)
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Figure 2. Apparent diffusion coefficient maps. A) Study before treatment, B) study during treatment. 39-year-old male patient with follicular lymphoma. 
ROIs placed in the tumour and in dorsal muscle as a reference. An increase of the ratio of approx. 6% was calculated. There was a progression of the disease 
in the follow-up and the patient died
A B
ability and agreement of MRI DWI/ADC with PET­CT 
[14]. Different results were stated by investigators from 
Finland. Wu et al. indicated superiority of the measure­
ments of the standardised uptake value (SUV) of 2­deoxy­
2­[18F]fluoro­D­glucose (18F­FDG) against DWI/ADC in 
patients with diffuse large B­cell lymphoma and follicular 
lymphoma. There were weak inversed correlations be­
tween the SUVmax and ADCmin in all cases, but it was not 
repeated in subgroups [9] MTV. The prognostic feature 
of the DWI/ADC was the subject of the study performed 
on the group of 28 patients with primary central nervous 
system lymphoma. It was investigated which DWI/ADC 
rank or parameter is a better biomarker of the response to 
treatment. It was revealed that DWI/ADC 5th percentiles 
are good predictors for progression­free survival. 
The early response to treatment is an important in­
dicator of a patient’s condition and prognosis [15]. Ap­
propriately quick assessment enables modification of the 
treatment protocol and if necessary adjustment to pa­
tient’s needs. In this study we evaluated weather the ADC 
measured on the first day of the second cycle of chemo­
therapy could be a predictor of prognosis and of the final 
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treatment’s outcome. There was a statistically significant 
difference between the DWI/ADC values in groups with 
Hodgkin’s and non­Hodgkin’s lymphomas. Patients with 
HL had higher values of DWI/ADC before and after the 
treatment (respectively, p = 0.027 and p = 0.029). Simi­
lar results were obtained in other studies [1, 16, 17] i.e., 
indolent versus aggressive lymphoma, and also to assess 
the prognostic value of different quantitative parameters 
of whole­body. Our results indicated that patients with 
ADC > 752 mm2/s before treatment demonstrated low­
er probability of progression than the patients with ADC 
< 752 mm2/s (p = 0.046). Mosavi et al. similarly reported 
a significant relationship between higher mean ADC and 
longer overall survival (p = 0.006) [16]. An increase of the 
ADC by 34.5% after the second cycle of chemotherapy 
correlates with a better prognosis. This result has not been 
confirmed in other cancers. Multivariate analysis in head 
and neck cancer revealed that lower pre­treatment ADC 
was associated with a better response to treatment [16].
There were some limitations to this pilot study, such as 
the small number of patients with diagnosed non­Hodg­
kin’s lymphoma, or lack of histopathological results. 
Figure 4. Comparison of the apparent diffusion coefficient (ADC) values before and after the treatment in groups with non-Hodgkin’s lymphoma (Group A) 
and Hodgkin’s lymphoma (Group C) (Student’s t-test, samples)
AD
C
1400
1200
1000
900
800
600
Before After
T-test for dependent samples: t = –3.556, p = 0.002
AD
C
1000
900
800
700
600
500
400
Before After
T-test for dependent samples: t = –6.608, p = 0.0003
Mean Mean ± SE Mean 1.96*SEMean Mean ± SE Mean 1.96SE
A B
Table 2. Apparent diffusion coefficient (ADC) values before and after the treatment of patients with diagnosed Hodgkin’s and non-Hodgkin’s lymphoma 
(Student’s t-test)
Parameter Total, N = 27 Type of lymphoma A vs. C
A (non-Hodgkin’s), n = 19 C (Hodgkin’s), n = 8
ADC before treatment
p = 0.027
M ± SD 720 ± 179 768 ± 176 604 ± 132
Me (Q1; Q3) 710 (572; 780) 732 (675; 840) 571 (533; 729)
Min-Max 388-1117 480-1117 388-780
ADC after treatment
p = 0.029
M ± SD 1059 ± 414 1164 ± 442 810 ± 184
Me (Q1; Q3) 980 (750; 1235) 1115 (790; 1377) 775 (688; 963)
Min-Max 549-2098 568-2098 549-1080
Odds ratio before treatment
p = 0.004
M ± SD 0.576 ± 0.155 0.630 ± 0.147 0.450 ± 0.086
Me (Q1; Q3) 0.53 (0.45; 0.71) 0.61 (0.52; 0.77) 0.43 (0.40; 0.51)
Min-Max 0.32-0.94 0.39-0.94 0.32-0.60
Odds ratio after treatment
p = 0.061
M ± SD 0.791 ± 0.348 0.872 ± 0.383 0.599 ± 0.117
Me (Q1; Q3) 0.65 (0.56; 1.07) 0.79 (0.61; 1.23) 0.58 (0.53; 0.65)
Min-Max 0.11-1.54 0.11-1.54 0.45-0.82
M – mean value, SD – standard dimension, Me – median, Q1 – lower quartile, Q3 – upper quartile, Min – minimum value, Max – maximum value, p – p-value
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Moreover, a whole­body MRI was not available at the time 
of examination and MRI was performed only within the 
range of interest.
Conclusions
Measurements of the ADC values before treatment and 
on the first day of the second cycle of chemotherapy can 
be used as a prognostic marker in the therapy of lympho­
mas. The most promising tool for assessing response to 
treatment seems to be the ratio between the ADC value 
measured in the area of infiltration and the ADC value 
of the reference organ (in our case – dorsal muscles). We 
calculated that an increase of the ratio lower than 32.5% 
could serve as a poor prognostic factor and could lead 
to modification of treatment. Early DWI/ADC measure­
ments enable shortening of the diagnostic process, thus 
obtaining a quicker assessment of prognosis. An early re­
sponse to treatment can influence further therapy and can 
potentially increase the chances for regression of lympho­
ma. The results seem to be promising, but further studies 
with larger groups of patients and long­term follow­up are 
essential to prove the usefulness of the DWI/ADC meas­
urements in the evaluation of lymphoma.
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